-
1 Comment
Rafael Holdings, Inc is currently in a long term uptrend where the price is trading 74.8% above its 200 day moving average.
From a valuation standpoint, the stock is 89.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 146.9.
Rafael Holdings, Inc's total revenue sank by 22.4% to $959K since the same quarter in the previous year.
Its net income has dropped by 551.6% to $-8M since the same quarter in the previous year.
Finally, its free cash flow fell by 167.0% to $-3M since the same quarter in the previous year.
Based on the above factors, Rafael Holdings, Inc gets an overall score of 2/5.
| CurrencyCode | USD |
|---|---|
| ISIN | US75062E1064 |
| Exchange | NYSE |
| Sector | Real Estate |
| Industry | Real Estate Services |
| Beta | 0.99 |
|---|---|
| Market Cap | 53M |
| PE Ratio | None |
| Target Price | None |
| Dividend Yield | None |
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), a stable analog of transient, acylated catalytic intermediates of lipoate currently under phase 2 open-label multi-cohort study evaluating CPI-613 in combination with hydroxychloroquine and 5-fluorouracil or gemcitabine in patients with advanced chemorefractory colorectal, pancreatic, or other solid cancers; and under phase 1 dose-escalation study of CPI-613 in combination with chemoradiation in patients with pancreatic adenocarcinoma. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for RFL using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
